Evidence‑Based Laboratory Evaluation for Fatigue

Assessment of Fatigue Severity

Use a 0–10 numeric rating scale to quantify fatigue before ordering any laboratory tests; this approach is supported by oncology guidelines. [1][2]
Order laboratory testing primarily when the fatigue score is ≥ 4, tailoring the panel to accompanying symptoms, onset pattern, and severity. 1

Core Laboratory Panel (Indicated When Fatigue ≥ 4)

Complete Blood Count with Differential

Measure hemoglobin/hematocrit to screen for anemia as a treatable cause of fatigue. 1
Compare current CBC values with prior baseline measurements, especially in cancer survivors, to detect new or worsening hematologic abnormalities. 1
Evaluate white‑blood‑cell and platelet counts to identify other hematologic disorders that may contribute to fatigue. 1

Comprehensive Metabolic Panel

Assess serum electrolytes (sodium, potassium, chloride, bicarbonate) to identify metabolic disturbances linked to fatigue. 1
Evaluate hepatic function through liver enzymes and bilirubin levels. 1
Assess renal function via serum creatinine and blood urea nitrogen. 1

Thyroid Function Testing

Measure thyroid‑stimulating hormone (TSH) as the primary screening test for thyroid dysfunction in fatigued patients. [1][2]
Reserve a more extensive endocrine work‑up or specialist referral for patients with additional signs suggestive of hypothyroidism, hypogonadism, adrenal insufficiency, or hypopituitarism—particularly those receiving immunotherapy. [1][2]3

Context‑Specific Additional Testing

Urinary or Metabolic Concerns

Perform a urinalysis (protein, blood, glucose) when urinary symptoms or metabolic abnormalities are suspected. 2

Suspected Inflammatory Conditions

Order inflammatory markers (erythrocyte sedimentation rate, C‑reactive protein) when clinical features point toward an inflammatory process. 2

Patients Treated with Immune Checkpoint Inhibitors

The Society for Immunotherapy of Cancer recommends, for patients on immune checkpoint inhibitors who develop new or worsening fatigue, a panel that includes CBC, comprehensive metabolic panel, TSH, free thyroxine, morning cortisol, and adrenocorticotropic hormone to evaluate immune‑related adverse events. 3

Non‑Laboratory Assessment Components (Supported by Oncology Guidelines)

Review all current medications for fatigue‑inducing effects (e.g., sleep aids, analgesics, antiemetics). 1
Screen for alcohol and substance use that may contribute to fatigue. 1
Evaluate nutritional status and recent weight changes. 1
Assess sleep quality and disturbances such as insomnia, sleep apnea, or vasomotor symptoms. 1
Screen for emotional distress, depression, and anxiety using validated tools, given their frequent contribution to fatigue. 1
Evaluate functional status and activity level to contextualize fatigue severity. 1

Clinical Decision‑Making

The decision to order laboratory tests should be based on clinical judgment, incorporating the pattern of fatigue onset, associated symptoms, and severity rather than reflexive testing. 1

Guideline for Laboratory Evaluation of Fatigue

Screening and Decision to Test

Quantify fatigue severity with a 0‑10 numeric rating scale; scores 4‑6 denote moderate fatigue and scores 7‑10 denote severe fatigue that warrants a comprehensive assessment. 4, 5
Order laboratory evaluation based on the presence of additional symptoms, the pattern of onset, and fatigue severity rather than reflexively ordering tests. 6, 7

Core Laboratory Panel

Complete Blood Count with Differential

Include hemoglobin/hematocrit measurement to screen for anemia as a potential contributor to fatigue. 6, 7
Include platelet count assessment to evaluate other hematologic cell lines. 7

Comprehensive Metabolic Panel

Assess electrolyte levels to identify treatable disturbances that may cause fatigue. 7, 5
Evaluate hepatic function (liver enzymes and bilirubin) to detect liver‑related contributors. 6, 7
Assess renal function (creatinine and BUN) to identify kidney‑related contributors. 7, 5
Measure fasting blood glucose to screen for dysglycemia as a fatigue factor. 5

Endocrine Evaluation

Measure thyroid‑stimulating hormone (TSH) as the primary screening test for thyroid dysfunction. 6, 7, 5
Reserve comprehensive endocrine panels or specialist referral for patients with additional symptoms suggesting specific endocrine disorders (e.g., hypothyroidism, hypogonadism, adrenal insufficiency). 7, 5

Additional Testing Based on Clinical Context

Perform urinalysis (protein, blood, glucose) when urinary symptoms or metabolic concerns are present. 5
Consider inflammatory markers (erythrocyte sedimentation rate, C‑reactive protein) when an inflammatory condition is suspected. 5

Assessment Beyond Laboratory Testing

Review current medications (including sleep aids, analgesics, antiemetics) for potential fatigue‑inducing effects. 6, 7
Screen for alcohol and other substance use that may contribute to fatigue. 6, 7
Evaluate nutritional status and recent weight changes as possible contributors. 6, 7
Assess sleep quality and disturbances as a common cause of persistent fatigue. 7, 5
Screen for emotional distress, depression, and anxiety, which are frequent contributors to fatigue. 7, 5
Evaluate functional status and activity level to contextualize fatigue severity. 6, 7

Guideline‑Recommended Evaluation of Fatigue in Adults

Severity Assessment

Core Laboratory Panel (indicated when fatigue score ≥ 4)

Complete Blood Count (CBC) with Differential

Comprehensive Metabolic Panel (CMP)

Thyroid Function Testing

Symptom‑Driven Additional Testing (performed only when specific symptoms are present)

Non‑Laboratory Assessment Components

Medication and Substance Review

Mental Health Screening

Nutritional and Activity Evaluation

Focused Fatigue History

Guideline Evidence and Recommendations

Guideline for Evaluation and Management of Unexplained Extreme Fatigue

1. Initial Assessment After Basic Labs Are Normal

After excluding anemia, thyroid dysfunction, vitamin D deficiency, and basic metabolic abnormalities, the work‑up should focus on sleep disorders, mood disorders, medication effects, cardiac dysfunction, and occult inflammatory or malignant conditions. 10, 11
Quantify fatigue on a 0–10 numeric scale; a score ≥ 4 warrants a comprehensive evaluation, and a score ≥ 7 indicates severe functional impairment that requires urgent assessment. 11, 12

2. Focused History and Symptom Screening

Sleep‑Related Evaluation

Screen for insomnia, obstructive sleep‑apnea symptoms (snoring, witnessed apneas, morning headaches), restless‑legs syndrome, and vasomotor symptoms that disrupt sleep. 10, 11
Arrange a formal polysomnography when clinical features suggest obstructive sleep apnea. 10

Mental‑Health Evaluation

Use validated anxiety screening tools; patients who are younger, have a prior psychiatric history, or low socioeconomic status are at higher risk and need more probing. 13, 10

Medication and Substance Review

Review all current medications for fatigue‑inducing potential, especially sleep aids, opioid analgesics, anti‑emetics, antihistamines, and benzodiazepines. 10, 11
Assess alcohol and other substance use as contributors to fatigue. 10, 11

Pain and Functional Status

Apply a simple pain scale and obtain a comprehensive pain history because chronic pain commonly contributes to fatigue. 13, 10
Document recent weight changes, caloric intake, and activity level to identify deconditioning. 10, 11

3. Targeted Laboratory and Imaging Studies

Cardiac Evaluation

Order an echocardiogram when the patient has a history of cardiotoxic chemotherapy, hypertension, coronary‑artery‑disease risk factors, or symptoms of heart failure (dyspnea, orthopnea, edema). 13, 10
Consider an exercise stress test to assess cardiopulmonary reserve if cardiac dysfunction is suspected. 10

Inflammatory Markers

Measure erythrocyte‑sedimentation rate (ESR) and C‑reactive protein (CRP) when features suggest inflammatory arthritis, polymyalgia rheumatica, or other inflammatory conditions. 10

Expanded Endocrine Testing (When Indicated)

Obtain a morning cortisol level and consider an ACTH stimulation test if adrenal insufficiency is suspected (orthostatic symptoms, hyperpigmentation, salt craving). 10
Check serum testosterone in men with decreased libido, erectile dysfunction, or loss of muscle mass. 10
Measure hemoglobin A1C if recent diabetes screening is lacking. 10

Additional Endocrine Considerations

A normal TSH does not exclude all endocrine causes; broader endocrine evaluation should be pursued when clinical suspicion persists. 10, 14
Patients receiving immune‑checkpoint inhibitors require an expanded endocrine panel (TSH, free T4, morning cortisol, ACTH) because fatigue may signal immune‑related adverse events. 14

Oncology Surveillance

Cancer survivors should be evaluated for disease recurrence if new or worsening fatigue appears > 6–12 months after treatment, especially with weight loss, pain, or pulmonary complaints. 12, 15

4. Evidence‑Based Therapeutic Interventions

Physical Activity Prescription

Recommend ≥ 150 minutes per week of moderate‑intensity aerobic exercise (e.g., brisk walking, cycling, swimming) plus 2–3 strength‑training sessions. 10, 11
Walking programs are safe for most patients without formal exercise testing; refer high‑risk individuals (e.g., neuropathy, cardiomyopathy) to physical therapy first. 10

Mind‑Body and Behavioral Therapies

Refer for cognitive‑behavioral therapy (CBT), which has demonstrated efficacy in reducing fatigue. 13, 10
Mindfulness‑based approaches, yoga, and acupuncture are supported by evidence as adjunctive fatigue‑reducing modalities. 10

Prioritizing Modifiable Contributors

Address sleep disturbances, pain, depression, and anxiety before labeling fatigue as idiopathic. 10, 11, 12
Optimize or discontinue fatigue‑inducing medications whenever feasible. 10

5. Specialist Referral Pathways

Sleep Medicine – when a sleep disorder is suspected. 10
Psychiatry / Psychology – for refractory depression or anxiety. 13, 10
Physical Medicine & Rehabilitation (Physiatry) – for severe fatigue that interferes with daily function. 10
Cardiology – if cardiac dysfunction is identified on evaluation. 13, 10

Laboratory and Clinical Assessment of Fatigue in Adults

Severity Assessment

Use a 0–10 numeric rating scale before ordering any laboratory tests; scores 1–3 denote mild fatigue, 4–6 moderate fatigue, and 7–10 severe fatigue that warrants comprehensive evaluation. 16

Core Laboratory Panel (for patients with fatigue score ≥ 4)

Hematology

Measure hemoglobin and hematocrit to screen for anemia, the most common treatable hematologic cause of fatigue. 16
Compare current complete blood count results with prior baseline values to detect new or worsening hematologic abnormalities, especially in individuals with a history of cancer or chronic disease. 16
Evaluate white‑blood‑cell and platelet counts to identify other hematologic disorders that may contribute to fatigue. 16

Metabolic Chemistry

Assess serum electrolytes (sodium, potassium, chloride, bicarbonate) to identify metabolic disturbances linked to fatigue. 16
Evaluate hepatic function through liver enzymes (AST, ALT, alkaline phosphatase) and bilirubin levels. 16
Assess renal function via serum creatinine and blood urea nitrogen. 16

Endocrine Screening

Measure thyroid‑stimulating hormone (TSH) as the primary screening test for thyroid dysfunction in all patients presenting with fatigue. [16][17]

Medication and Substance Review

Review all current medications for fatigue‑inducing potential, with particular attention to sleep aids, opioid analgesics, antiemetics, antihistamines, and benzodiazepines. 16

Mental Health Screening

Screen for depression and anxiety using validated instruments, as these conditions are frequent primary contributors to chronic fatigue. 16

Nutritional and Activity Assessment

Evaluate overall nutritional status, recent weight changes, and caloric intake to identify possible dietary contributors to fatigue. 16
Assess current activity level and functional status to detect deconditioning that may be a modifiable cause of fatigue. 16

Focused Fatigue History

Document the onset, pattern, duration, and any temporal associations or alleviating factors of fatigue to differentiate acute from chronic presentations. 16

Cancer Survivor Follow‑up

Review disease status by considering stage, pathologic factors, and prior treatment history when new or worsening fatigue appears > 6–12 months after therapy completion, to evaluate the risk of disease recurrence. 16

Assessment and Management of Chronic Fatigue in Elderly Patients

Assessment Tools

Numeric rating scale for fatigue severity – Use a 0‑10 scale (0 = no fatigue, 10 = worst imaginable); scores 4‑6 denote moderate fatigue, while scores 7‑10 denote severe fatigue that warrants a comprehensive evaluation. 18
Tracking and work‑up guidance – Applying the numeric rating scale allows clinicians to monitor fatigue over time and to determine the intensity of the diagnostic work‑up (e.g., when to move beyond basic laboratory testing). 18

Focused History

Functional impact of fatigue – Record whether the patient’s fatigue is disproportionate to recent activity and interferes with usual daily functioning. This helps differentiate pathologic fatigue from normal age‑related tiredness. 18

Patient Education

Multifactorial nature of fatigue – Explain to patients that fatigue in older adults results from a combination of biological, psychological, and social factors. 19
Self‑monitoring – Instruct patients to record their daily fatigue level using the 0‑10 scale, which facilitates early detection of worsening symptoms and prompts timely clinical review. 18

Endocrine and Metabolic Laboratory Recommendations for Chronic Fatigue

General Endocrine Work‑up for Chronic Fatigue

In patients with chronic fatigue who also exhibit symptoms suggestive of hypothyroidism (e.g., cold intolerance, weight gain, constipation, hair loss), adrenal insufficiency (e.g., orthostatic symptoms, hyperpigmentation, salt craving), or hypogonadism (e.g., decreased libido, erectile dysfunction), the core panel should be expanded to include free T4, a morning cortisol level, and ACTH measurement to identify treatable endocrine disorders. [20][21]

Immune Checkpoint Inhibitor–Associated Fatigue

For individuals receiving immune checkpoint inhibitor therapy, a mandatory expanded endocrine panel—comprising TSH, free T4, morning cortisol (ideally drawn around 8 AM), and ACTH—is recommended to detect immune‑related adverse events, because fatigue occurs in approximately 66 % of patients who develop hypophysitis. [20][22]
When hypophysitis is suspected on the basis of low TSH together with low free T4, clinicians should consider a cosyntropin stimulation test and measurement of gonadal hormones (testosterone in men, estradiol in women) as well as FSH and LH to assess pituitary‑adrenal and pituitary‑gonadal axis involvement. [21][22]

Management of Coexisting Adrenal Insufficiency and Hypothyroidism

In patients diagnosed with both adrenal insufficiency and hypothyroidism, corticosteroid therapy should be initiated before thyroid hormone replacement to prevent precipitating an adrenal crisis. [20][21]

Inflammatory Bowel Disease–Related Fatigue

For patients with inflammatory bowel disease who report fatigue, routine monitoring of iron stores, hemoglobin, and inflammatory markers (e.g., CRP, ESR) is advised even in the absence of active bowel symptoms, because persistent iron deficiency or elevated inflammatory markers represent reversible contributors to fatigue. 23